Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (UNAUDITED)

v3.19.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)
Common Stock
Preferred Stock
Additional Paid-in Capital
Accumulated Deficit
Stockholders' Deficit-TransBiotech Inc.
Total
Noncontrolling Interest
Beginning balance, Shares at Dec. 31, 2016 67,751,068            
Beginning balance, Amount at Dec. 31, 2016 $ 677   $ 14,095,430 $ (17,064,086) $ (2,967,979) $ (3,011,880) $ (43,901)
Common stock issued for cash, Shares 7,171,429            
Common stock issued for cash, Amount $ 72   50,128 50,200 50,200
Common Stock issued due to options exercise, Shares 32,248,932            
Common Stock issued due to options exercise, Amount $ 323   112,548 112,871 112,871
Paid-in capital - fair value of stock warrants granted     75,718 75,718 75,718
Paid-in capital - fair value of stock compensation     6,290 6,290 6,290
Paid-in capital - Gain on related party debt conversion     164,297 164,297 164,297
Paid-in capital - beneficial conversion feature     21,500 21,500 21,500
Paid-in capital - reclassification of common share equivalents to derivative liabilities     (199,919) (199,919) (199,919)
Paid-in capital - reclassification of derivative liabilities to common share equivalents     504,263 504,263 504,263
Share exchange - noncontrolling interest     (2,019) (2,019)
Net loss       (533,090) (533,090) (533,090)
Ending balance, Shares at Jun. 30, 2017 107,171,429            
Ending balance, Amount at Jun. 30, 2017 $ 1,072   14,830,255 (17,597,176) (2,765,849) (2,811,769) (45,920)
Beginning balance, Shares at Dec. 31, 2017 109,409,930 1,388,575          
Beginning balance, Amount at Dec. 31, 2017 $ 1,096 $ 14 14,785,051 (17,703,171) (2,917,010) (2,964,137) (47,127)
Common Stock issued due to options exercise, Shares 450,000            
Common Stock issued due to options exercise, Amount $ 5   4,495 4,500 4,500
Paid-in capital - fair value of stock warrants granted     29,701 29,701 29,701
Paid-in capital - Gain on related party debt conversion     15,143 15,143 15,143
Paid-in capital - beneficial conversion feature     6,000 6,000 6,000
Share exchange - noncontrolling interest     (1,625) (1,625)
Common stock issued for services, Shares 6,000,000            
Common stock issued for services, Amount $ 61   25,739 25,800 25,800
Common stock issued for compensation, Shares 800,000            
Common stock issued for compensation, Amount $ 9   7,991 8,000 8,000
Common stock issued to settle accounts payable, Shares 91,148            
Common stock issued to settle accounts payable, Amount $ 1   427 428 428
Net loss     (293,859) (293,859) (293,859)
Ending balance, Shares at Jun. 30, 2018 116,751,078 1,388,575          
Ending balance, Amount at Jun. 30, 2018 $ 1,172 $ 14 $ 14,874,547 $ (17,997,030) $ (3,121,297) $ (3,170,049) $ (48,752)